Entry
Name
Coronavirus disease - COVID-19 - Mus musculus (house mouse)
Description
Coronavirus disease of 2019 (COVID-19) is a highly contagious respiratory infection that is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 infects alveolar epithelial cells [mainly alveolar epithelial type 2 (AEC2) cells] through the angiotensin-converting enzyme 2 (ACE2) receptor. Upon the occupancy of ACE2 by SARS-CoV-2, the increased serum level of free Angiotensin II (Ang II) due to a reduction of ACE2-mediated degradation promotes activation of the NF-kappa B pathway via Ang II type 1 receptor (AT1R), followed by interleukin-6 (IL-6) production. SARS-CoV-2 also activates the innate immune system; macrophage stimulation triggers the overproduction of pro-inflammatory cytokines, including IL-6, and the "cytokine storm", which results in systemic inflammatory response syndrome and multiple organ failure. The combined effects of complement activation, dysregulated neutrophilia, endothelial injury, and hypercoagulability appear to be intertwined to drive the severe features of COVID-19.
Class
Human Diseases; Infectious disease: viral
BRITE hierarchy
Pathway map
Ortholog table
Organism
Mus musculus (house mouse) [GN:
mmu ]
Gene
11607 Agtr1a; angiotensin II receptor, type 1a [KO:K04166 ]
11608 Agtr1b; angiotensin II receptor, type 1b [KO:K04166 ]
13058 Cybb; cytochrome b-245, beta polypeptide [KO:K21421 ] [EC:1.-.-.-]
18033 Nfkb1; nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 [KO:K02580 ]
19697 Rela; v-rel reticuloendotheliosis viral oncogene homolog A (avian) [KO:K04735 ]
21937 Tnfrsf1a; tumor necrosis factor receptor superfamily, member 1a [KO:K03158 ]
18035 Nfkbia; nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha [KO:K04734 ]
18036 Nfkbib; nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, beta [KO:K02581 ]
15200 Hbegf; heparin-binding EGF-like growth factor [KO:K08523 ]
16195 Il6st; interleukin 6 signal transducer [KO:K05060 ]
20848 Stat3; signal transducer and activator of transcription 3 [KO:K04692 ]
12985 Csf3; colony stimulating factor 3 (granulocyte) [KO:K05423 ]
12981 Csf2; colony stimulating factor 2 (granulocyte-macrophage) [KO:K05427 ]
15945 Cxcl10; C-X-C motif chemokine ligand 10 [KO:K12671 ]
20102 Rps4x; ribosomal protein S4, X-linked [KO:K02987 ]
670832 Rps12-ps10; ribosomal protein S12, pseudogene 10 [KO:K02951 ]
434843 Rps12-ps11; ribosomal protein S12, pseudogene 11 [KO:K02951 ]
665463 Rps12-ps12; ribosomal protein S12, pseudogene 12 [KO:K02951 ]
665522 Rps12-ps15; ribosomal protein S12, pseudogene 15 [KO:K02951 ]
665579 Rps12-ps13; ribosomal protein S12, pseudogene 13 [KO:K02951 ]
665611 Rps12-ps14; ribosomal protein S12, pseudogene 14 [KO:K02951 ]
626048 Rps12-ps16; ribosomal protein S12, pseudogene 16 [KO:K02951 ]
671641 Rps12-ps24; ribosomal protein S12, pseudogene 24 [KO:K02951 ]
14109 Fau; FAU ubiquitin like and ribosomal protein S30 fusion [KO:K02983 ]
68028 Rpl22l1; ribosomal protein L22 like 1 [KO:K02891 ]
225215 Rsl24d1; ribosomal L24 domain containing 1 [KO:K02896 ]
665562 Rpl31-ps12; ribosomal protein L31, pseudogene 1 2 [KO:K02910 ]
619547 Rpl34-ps1; ribosomal protein L34, pseudogene 1 [KO:K02915 ]
22186 Uba52; ubiquitin A-52 residue ribosomal protein fusion product 1 [KO:K02927 ]
11837 Rplp0; ribosomal protein lateral stalk subunit P0 [KO:K02941 ]
56040 Rplp1; ribosomal protein lateral stalk subunit P1 [KO:K02942 ]
67186 Rplp2; ribosomal protein lateral stalk subunit P2 [KO:K02943 ]
14131 Fcgr3; Fc receptor, IgG, low affinity III [KO:K06472 ]
18706 Pik3ca; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha [KO:K00922 ] [EC:2.7.1.153 ]
18707 Pik3cd; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta [KO:K00922 ] [EC:2.7.1.153 ]
74769 Pik3cb; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta [KO:K00922 ] [EC:2.7.1.153 ]
18709 Pik3r2; phosphoinositide-3-kinase regulatory subunit 2 [KO:K02649 ]
18708 Pik3r1; phosphoinositide-3-kinase regulatory subunit 1 [KO:K02649 ]
18710 Pik3r3; phosphoinositide-3-kinase regulatory subunit 3 [KO:K02649 ]
17874 Myd88; myeloid differentiation primary response gene 88 [KO:K04729 ]
68652 Tab2; TGF-beta activated kinase 1/MAP3K7 binding protein 2 [KO:K04404 ]
16151 Ikbkg; inhibitor of kappaB kinase gamma [KO:K07210 ]
216799 Nlrp3; NLR family, pyrin domain containing 3 [KO:K12800 ]
228607 Mavs; mitochondrial antiviral signaling protein [KO:K12648 ]
22031 Traf3; TNF receptor-associated factor 3 [KO:K03174 ]
72512 Sting1; stimulator of interferon response cGAMP interactor 1 [KO:K12654 ]
15975 Ifnar1; interferon (alpha and beta) receptor 1 [KO:K05130 ]
15976 Ifnar2; interferon (alpha and beta) receptor 2 [KO:K05131 ]
20846 Stat1; signal transducer and activator of transcription 1 [KO:K11220 ]
20847 Stat2; signal transducer and activator of transcription 2 [KO:K11221 ]
19106 Eif2ak2; eukaryotic translation initiation factor 2-alpha kinase 2 [KO:K16195 ] [EC:2.7.11.1 ]
12273 C5ar1; complement component 5a receptor 1 [KO:K04010 ]
12267 C3ar1; complement component 3a receptor 1 [KO:K04009 ]
230558 C8a; complement component 8, alpha polypeptide [KO:K03997 ]
110382 C8b; complement component 8, beta polypeptide [KO:K03998 ]
69379 C8g; complement component 8, gamma polypeptide [KO:K03999 ]
12259 C1qa; complement component 1, q subcomponent, alpha polypeptide [KO:K03986 ]
12260 C1qb; complement component 1, q subcomponent, beta polypeptide [KO:K03987 ]
12262 C1qc; complement component 1, q subcomponent, C chain [KO:K03988 ]
12268 C4b; complement C4B (Chido blood group) [KO:K03989 ]
625018 C4a; complement C4A (Rodgers blood group) [KO:K03989 ]
17194 Mbl1; mannose-binding lectin (protein A) 1 [KO:K03991 ]
17195 Mbl2; mannose-binding lectin (protein C) 2 [KO:K03991 ]
17174 Masp1; MBL associated serine protease 1 [KO:K03992 ] [EC:3.4.21.-]
14060 F13b; coagulation factor XIII, beta subunit [KO:K03906 ]
Compound
Reference
Authors
Harrison AG, Lin T, Wang P
Title
Mechanisms of SARS-CoV-2 Transmission and Pathogenesis.
Journal
Reference
Authors
Perico L, Benigni A, Casiraghi F, Ng LFP, Renia L, Remuzzi G
Title
Immunity, endothelial injury and complement-induced coagulopathy in COVID-19.
Journal
Reference
Authors
Battagello DS, Dragunas G, Klein MO, Ayub ALP, Velloso FJ, Correa RG
Title
Unpuzzling COVID-19: tissue-related signaling pathways associated with SARS-CoV-2 infection and transmission.
Journal
Reference
Authors
Felsenstein S, Herbert JA, McNamara PS, Hedrich CM
Title
COVID-19: Immunology and treatment options.
Journal
Reference
Authors
Hojyo S, Uchida M, Tanaka K, Hasebe R, Tanaka Y, Murakami M, Hirano T
Title
How COVID-19 induces cytokine storm with high mortality.
Journal
Reference
Authors
Mahmudpour M, Roozbeh J, Keshavarz M, Farrokhi S, Nabipour I
Title
COVID-19 cytokine storm: The anger of inflammation.
Journal
Reference
Authors
Farooqi F, Dhawan N, Morgan R, Dinh J, Nedd K, Yatzkan G
Title
Treatment of Severe COVID-19 with Tocilizumab Mitigates Cytokine Storm and Averts Mechanical Ventilation During Acute Respiratory Distress: A Case Report and Literature Review.
Journal
Reference
Authors
Jamilloux Y, Henry T, Belot A, Viel S, Fauter M, El Jammal T, Walzer T, Francois B, Seve P
Title
Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions.
Journal
Reference
Authors
Kiselevskiy M, Shubina I, Chikileva I, Sitdikova S, Samoylenko I, Anisimova N, Kirgizov K, Suleimanova A, Gorbunova T, Varfolomeeva S
Title
Immune Pathogenesis of COVID-19 Intoxication: Storm or Silence?
Journal
Reference
Authors
Curran CS, Rivera DR, Kopp JB
Title
COVID-19 Usurps Host Regulatory Networks.
Journal
Reference
Authors
Quan C, Li C, Ma H, Li Y, Zhang H
Title
Immunopathogenesis of Coronavirus-Induced Acute Respiratory Distress Syndrome (ARDS): Potential Infection-Associated Hemophagocytic Lymphohistiocytosis.
Journal
Reference
Authors
Ahmed-Hassan H, Sisson B, Shukla RK, Wijewantha Y, Funderburg NT, Li Z, Hayes D Jr, Demberg T, Liyanage NPM
Title
Innate Immune Responses to Highly Pathogenic Coronaviruses and Other Significant Respiratory Viral Infections.
Journal
Reference
Authors
Tay MZ, Poh CM, Renia L, MacAry PA, Ng LFP
Title
The trinity of COVID-19: immunity, inflammation and intervention.
Journal
Reference
Authors
Xia H, Cao Z, Xie X, Zhang X, Chen JY, Wang H, Menachery VD, Rajsbaum R, Shi PY
Title
Evasion of Type I Interferon by SARS-CoV-2.
Journal
Reference
Authors
Hartenian E, Nandakumar D, Lari A, Ly M, Tucker JM, Glaunsinger BA
Title
The molecular virology of coronaviruses.
Journal
Reference
Authors
Amor S, Fernandez Blanco L, Baker D
Title
Innate immunity during SARS-CoV-2: evasion strategies and activation trigger hypoxia and vascular damage.
Journal
Reference
Authors
Catanzaro M, Fagiani F, Racchi M, Corsini E, Govoni S, Lanni C
Title
Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2.
Journal
Reference
Authors
Jafarzadeh A, Chauhan P, Saha B, Jafarzadeh S, Nemati M
Title
Contribution of monocytes and macrophages to the local tissue inflammation and cytokine storm in COVID-19: Lessons from SARS and MERS, and potential therapeutic interventions.
Journal
Reference
Authors
Merad M, Martin JC
Title
Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages.
Journal
Reference
Authors
South AM, Tomlinson L, Edmonston D, Hiremath S, Sparks MA
Title
Controversies of renin-angiotensin system inhibition during the COVID-19 pandemic.
Journal
Reference
Authors
Furuhashi M, Moniwa N, Takizawa H, Ura N, Shimamoto K
Title
Potential differential effects of renin-angiotensin system inhibitors on SARS-CoV-2 infection and lung injury in COVID-19.
Journal
Reference
Authors
Gemmati D, Bramanti B, Serino ML, Secchiero P, Zauli G, Tisato V
Title
COVID-19 and Individual Genetic Susceptibility/Receptivity: Role of ACE1/ACE2 Genes, Immunity, Inflammation and Coagulation. Might the Double X-chromosome in Females Be Protective against SARS-CoV-2 Compared to the Single X-Chromosome in Males?
Journal
Reference
Authors
Kielian M
Title
Enhancing host cell infection by SARS-CoV-2.
Journal
Reference
Authors
Risitano AM, Mastellos DC, Huber-Lang M, Yancopoulou D, Garlanda C, Ciceri F, Lambris JD
Title
Complement as a target in COVID-19?
Journal
Reference
Authors
Noris M, Benigni A, Remuzzi G
Title
The case of complement activation in COVID-19 multiorgan impact.
Journal
Reference
Authors
Polycarpou A, Howard M, Farrar CA, Greenlaw R, Fanelli G, Wallis R, Klavinskis LS, Sacks S
Title
Rationale for targeting complement in COVID-19.
Journal
Reference
Authors
Teuwen LA, Geldhof V, Pasut A, Carmeliet P
Title
COVID-19: the vasculature unleashed.
Journal
Reference
Authors
Jodele S, Kohl J
Title
Tackling COVID-19 infection through complement-targeted immunotherapy.
Journal
Reference
Authors
Chauhan AJ, Wiffen LJ, Brown TP
Title
COVID-19: A collision of complement, coagulation and inflammatory pathways.
Journal
Reference
Authors
Colling ME, Kanthi Y
Title
COVID-19-associated coagulopathy: An exploration of mechanisms.
Journal
Reference
Authors
McFadyen JD, Stevens H, Peter K
Title
The Emerging Threat of (Micro)Thrombosis in COVID-19 and Its Therapeutic Implications.
Journal
Reference
Authors
Shi M, Wang L, Fontana P, Vora S, Zhang Y, Fu TM, Lieberman J, Wu H
Title
SARS-CoV-2 Nsp1 suppresses host but not viral translation through a bipartite mechanism.
Journal
Reference
Authors
Paniri A, Akhavan-Niaki H
Title
Emerging role of IL-6 and NLRP3 inflammasome as potential therapeutic targets to combat COVID-19: Role of lncRNAs in cytokine storm modulation.
Journal
Reference
Authors
Omarjee L, Janin A, Perrot F, Laviolle B, Meilhac O, Mahe G
Title
Targeting T-cell senescence and cytokine storm with rapamycin to prevent severe progression in COVID-19.
Journal
Reference
Authors
Zhang S, Li L, Shen A, Chen Y, Qi Z
Title
Rational Use of Tocilizumab in the Treatment of Novel Coronavirus Pneumonia.
Journal
Related pathway
mmu04270 Vascular smooth muscle contraction
mmu04610 Complement and coagulation cascades
mmu04613 Neutrophil extracellular trap formation
mmu04620 Toll-like receptor signaling pathway
mmu04621 NOD-like receptor signaling pathway
mmu04622 RIG-I-like receptor signaling pathway
mmu04650 Natural killer cell mediated cytotoxicity
mmu04666 Fc gamma R-mediated phagocytosis
mmu04670 Leukocyte transendothelial migration
KO pathway
LinkDB
All DBs